BR0309342A - Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas - Google Patents

Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas

Info

Publication number
BR0309342A
BR0309342A BR0309342-5A BR0309342A BR0309342A BR 0309342 A BR0309342 A BR 0309342A BR 0309342 A BR0309342 A BR 0309342A BR 0309342 A BR0309342 A BR 0309342A
Authority
BR
Brazil
Prior art keywords
compound
prophylaxis
treating
conditions
pharmaceutical composition
Prior art date
Application number
BR0309342-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Hui-Fang Chang
Yan Li
Eifion Phillips
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201187A external-priority patent/SE0201187D0/xx
Priority claimed from SE0203608A external-priority patent/SE0203608D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0309342A publication Critical patent/BR0309342A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0309342-5A 2002-04-18 2003-04-15 Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas BR0309342A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0201187A SE0201187D0 (sv) 2002-04-18 2002-04-18 Thienyl compounds
SE0203608A SE0203608D0 (sv) 2002-12-04 2002-12-04 Thienyl compounds
PCT/SE2003/000614 WO2003087103A1 (en) 2002-04-18 2003-04-15 Thienyl compounds

Publications (1)

Publication Number Publication Date
BR0309342A true BR0309342A (pt) 2005-02-15

Family

ID=29253789

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309342-5A BR0309342A (pt) 2002-04-18 2003-04-15 Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas

Country Status (16)

Country Link
US (3) US7186836B2 (enExample)
EP (1) EP1499615B1 (enExample)
JP (1) JP4511196B2 (enExample)
KR (1) KR20040099448A (enExample)
CN (1) CN1325499C (enExample)
AT (1) ATE477256T1 (enExample)
AU (1) AU2003224545B2 (enExample)
BR (1) BR0309342A (enExample)
CA (1) CA2482312A1 (enExample)
DE (1) DE60333746D1 (enExample)
ES (1) ES2348282T3 (enExample)
IL (1) IL164613A0 (enExample)
MX (1) MXPA04010193A (enExample)
NO (1) NO20044997L (enExample)
NZ (1) NZ535978A (enExample)
WO (1) WO2003087103A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
NZ531786A (en) 2001-10-02 2006-10-27 Upjohn Co Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
CN1325499C (zh) * 2002-04-18 2007-07-11 阿斯特拉曾尼卡有限公司 噻吩基化合物
EP1499618B1 (en) * 2002-04-18 2010-10-13 AstraZeneca AB Furyl compounds
EP1678183A1 (en) * 2003-10-21 2006-07-12 AstraZeneca AB Spirofuropyridine aryl derivatives
US7045530B2 (en) 2003-12-22 2006-05-16 Abbott Laboratories Spirocyclic quinuclidinic ether derivatives
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
ES2402084T3 (es) 2008-06-20 2013-04-26 Astrazeneca Ab Derivado de dibenzotiazepina y sus usos
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN103221411B (zh) 2010-05-17 2016-05-11 富瑞姆制药公司 (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
ES2694299T3 (es) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
EA029430B1 (ru) 2013-06-21 2018-03-30 Такеда Фармасьютикл Компани Лимитед Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
CN112898312B (zh) * 2021-01-29 2021-11-12 湖南南新制药股份有限公司 一种稠合多环吡啶酮衍生物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
US20010016677A1 (en) * 1999-02-16 2001-08-23 Dan Russell Poole Incubator with thermoelectric cooler
US6569865B2 (en) * 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
DK1397366T3 (da) * 2001-06-01 2007-05-07 Astrazeneca Ab Hidtil ukendt ligander for nicotinacetylcholinreceptorer egnede i terapi
EP1499618B1 (en) * 2002-04-18 2010-10-13 AstraZeneca AB Furyl compounds
CN1325499C (zh) * 2002-04-18 2007-07-11 阿斯特拉曾尼卡有限公司 噻吩基化合物

Also Published As

Publication number Publication date
WO2003087103A1 (en) 2003-10-23
NZ535978A (en) 2007-10-26
DE60333746D1 (de) 2010-09-23
AU2003224545B2 (en) 2009-08-13
US20110124672A1 (en) 2011-05-26
JP4511196B2 (ja) 2010-07-28
CN1659170A (zh) 2005-08-24
HK1079522A1 (en) 2006-04-07
ATE477256T1 (de) 2010-08-15
JP2005527588A (ja) 2005-09-15
CN1325499C (zh) 2007-07-11
MXPA04010193A (es) 2005-02-03
NO20044997L (no) 2005-01-18
CA2482312A1 (en) 2003-10-23
EP1499615B1 (en) 2010-08-11
AU2003224545A1 (en) 2003-10-27
ES2348282T3 (es) 2010-12-02
US20070142419A1 (en) 2007-06-21
EP1499615A1 (en) 2005-01-26
IL164613A0 (en) 2005-12-18
US7186836B2 (en) 2007-03-06
KR20040099448A (ko) 2004-11-26
US20050171106A1 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
NO20044995L (no) Heterosykliske forbindelser
BR0313234A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, composição farmacêutica, e, processo para a preparação de um composto
GB0112348D0 (en) Compounds
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
BR0109703A (pt) Derivados de piperazina
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
SE0101387D0 (sv) Novel compounds
BR0309498A (pt) Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças que são relacionadas com o ras, e, uso de compostos
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
DK1483251T3 (da) C3-cyano-epothilon-derivater
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
BR0309757A (pt) 6-alquilideno-penemas bicìclicos como inibidores de beta-lactamases
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
SE0303480D0 (sv) Benzofuranes
BR0312470A (pt) Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto
BR0309878A (pt) Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase
SE0102057D0 (sv) New Salts I
NO20063619L (no) Diarylmetylpiperazinderivater, fremstilling og anvendelse derav

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 8A E 9A ANUIDADES.